Search
Aducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[A235668,A235730] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a reduction … Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-β plaques in the brain; similar to [gantenerumab], [bapineuzumab] and [solanezumab].
Bimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigationalBimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment
Cangrelor
go.drugbank.com/drugs/DB06441ApprovedInvestigationalCangrelor was approved by the FDA in June 2015 for intravenous application. … An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset
Brivudine
go.drugbank.com/drugs/DB03312ApprovedInvestigationalAlthough not approved in the U.S. or Canada, it is approved in several European countries.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseAntithymocyte immunoglobulin (rabbit)
go.drugbank.com/drugs/DB00098ApprovedInvestigationalThymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. … Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
Products: Thymoglobuline 5mg/ml Powder for concentrate for solution for infusionTezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigationalTezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector class. … Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.
Obecabtagene autoleucel
go.drugbank.com/drugs/DB17362ApprovedInvestigationalObecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19. … [A265050] On November 8, 2024, obecabtagene autoleucel was approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Synonyms: A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING O, AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODINGCorticotropin
go.drugbank.com/drugs/DB01285ApprovedInvestigationalVet approvedCorticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
Categories: Pro-Opiomelanocortin, Corticosteroids for Systemic UseDienestrol
go.drugbank.com/drugs/DB00890ApprovedWithdrawnUsing or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness, or soreness of the vulva. … Dienestrol is a synthetic, non-steroidal estrogen. It is an estrogen receptor agonist.
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalRanibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology … In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use.
Products: Lucentis 10mg/ml Solution for Injection, ACCENTRIX 10MG/ML SOLUTION FOR INJECTION